Please assess the completion status of the following clinical trial:

Trial Title: Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer~  * Progressive or recurrent disease~* Received ≥ 1 prior course of chemotherapy~* Measurable or evaluable disease OR disease assessable by CA 125, defined as CA 125 \> normal that has increased over 2 readings \> 14 days apart~* Karnofsky performance status 10-50%~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.5 mg/dL~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* SGOT ≤ 3 times ULN~* Life expectancy ≥ 12 weeks~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use accepted and effective non-hormonal contraception~Exclusion Criteria:~* Other neoplasm within the past 5 years except for nonmetastatic, nonmelanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or chemotherapy~* Septicemia, severe infection, or acute hepatitis~* Severe gastrointestinal bleeding, defined as requiring a blood transfusion or hospitalization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escalating Cohorts (Type: EXPERIMENTAL): Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD.

Based on this trial design, predict the completion outcome and termination type (if applicable).